98 related articles for article (PubMed ID: 19554862)
1. Assessing the safety and cost-effectiveness of early nanodrugs.
Vines T; Faunce T
J Law Med; 2009 May; 16(5):822-45. PubMed ID: 19554862
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
Lopert R
Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
[TBL] [Abstract][Full Text] [Related]
3. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
Sinha Y; Brien JA; Craig JC
J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
[TBL] [Abstract][Full Text] [Related]
4. Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceutical Benefits Advisory Committee.
Carter D; Vogan A; Haji Ali Afzali H
Appl Health Econ Health Policy; 2016 Aug; 14(4):401-407. PubMed ID: 26818196
[TBL] [Abstract][Full Text] [Related]
5. Review of a decision by the Medical Services Advisory Committee based on health technology assessment of an emerging technology: the case for remotely assisted radical prostatectomy.
O'Malley SP; Jordan E
Int J Technol Assess Health Care; 2007; 23(2):286-91. PubMed ID: 17493316
[TBL] [Abstract][Full Text] [Related]
6. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
Ghosh D; Skinner M; Ferguson LR
Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
Kim H; Byrnes J; Goodall S;
Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
[TBL] [Abstract][Full Text] [Related]
8. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
Lexchin J; Mintzes B
Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
[TBL] [Abstract][Full Text] [Related]
9. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.
Harris AH; Hill SR; Chin G; Li JJ; Walkom E
Med Decis Making; 2008; 28(5):713-22. PubMed ID: 18378939
[TBL] [Abstract][Full Text] [Related]
10. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
Langley PC
Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
[TBL] [Abstract][Full Text] [Related]
11. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
Chen ML
Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
[TBL] [Abstract][Full Text] [Related]
12. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
13. Australia's 'fourth hurdle' drug review comparing costs and benefits holds lessons for the United States.
Lopert R; Elshaug AG
Health Aff (Millwood); 2013 Apr; 32(4):778-87. PubMed ID: 23569059
[TBL] [Abstract][Full Text] [Related]
14. Recent legal developments and the authority of the Australian Therapeutic Goods Administration.
Shirlow E; Faunce T
J Law Med; 2009 May; 16(5):764-9. PubMed ID: 19554858
[TBL] [Abstract][Full Text] [Related]
15. PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA.
Turkstra E; Bettington E; Donohue ML; Mervin MC
Int J Technol Assess Health Care; 2017 Jan; 33(4):521-528. PubMed ID: 28703092
[TBL] [Abstract][Full Text] [Related]
16. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
Doran E; Alexander Henry D
J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
[TBL] [Abstract][Full Text] [Related]
17. Microbial limits reviewed: the basis for unique Australian regulatory requirements for microbial quality of non-sterile pharmaceuticals.
Tang S
PDA J Pharm Sci Technol; 1998; 52(3):100-9. PubMed ID: 9691672
[TBL] [Abstract][Full Text] [Related]
18. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
Verbeeck RK; Kanfer I; Walker RB
Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
Wonder M; Dunlop S
Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
[TBL] [Abstract][Full Text] [Related]
20. Delays in access to affordable medicines: putting policy into perspective.
Pearce A; van Gool K; Haywood P; Haas M
Aust Health Rev; 2012 Nov; 36(4):412-8. PubMed ID: 23062753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
